Protalix BioTherapeutics (NYSE:PLX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.
Protalix BioTherapeutics Stock Performance
Shares of NYSE PLX opened at $1.92 on Friday. The company has a quick ratio of 1.11, a current ratio of 3.18 and a debt-to-equity ratio of 0.52. Protalix BioTherapeutics has a 12 month low of $1.00 and a 12 month high of $3.55. The company has a market cap of $137.43 million, a price-to-earnings ratio of 96.05 and a beta of 1.35.
Protalix BioTherapeutics Company Profile
See Also
- Five stocks we like better than Protalix BioTherapeutics
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 8/7 – 8/11
- Which Wall Street Analysts are the Most Accurate?
- 3 Retailers To Watch Closely Next Week
- How to Invest and Trade Chinese Stocks
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
